We participate in numerous events promoting our portfolio companies and meeting our clients.

2013

APIM Therapeutics, a VP portfolio company, has completed a new financing round by existing investors Norsk Innovasjons-kapital III, Sarsia Seed, Birk Venture and Ro Invest. This financing will enable the company to continue development of ATX-101, its lead peptide drug, towards first-in-man clinical trials.

Avexxin's clinical trial in psoriasis continues: Danish Medicine Agency has authorized Avexxin to continue its phase I/IIa clinical trial employing additional doses in order to find the MTD. The extension of the trial encompasses three additional groups of patients and will be completed by April 2014.

Boulder Diagnostics, a VP portfolio company, introduces SpiroFind® Vet for active Lyme disease detection in dogs and horses and GoutiFind™, a new non-invasive diagnostic test for Gout disease. For a copy of the press release, please follow this link.

Avexxin AS, a VP portfolio company, has completed an additional series B round financing facilitated by Sparebank1 SMN Markets, Norway. This financing enables the company to continue its clinical trial phase I/IIa and further advance its other pre-clinical development programs.

Avexxin, a VP portfolio company, receives further grant of NOK 1.8 million from Innovation Norway in support of its clinical program against psoriasis.

Ventac Partners portfolio companies Avexxin and Zestagen have been selected to present at the Chicago BIO International Conference, April 22-25, 2013. BIO is the largest life science meeting in the world.

On February 20th 2013, Bilan, the prestigious Swiss economic review, selected Zestagen, a VP portfolio company, as #1 biotechcompany to invest in Switzerland. Zestagen, a Ventac Partners portfolio company, develops novel monoclonal antibodies for various oncology indications.

On January 29, 2013, the Danish Medicine Agency authorized Avexxin to conduct a randomized, double-blinded, placebo-controlled, sequential parallel group, dose-escalation, single centre first-in-man study to assess the safety and efficacy of Avexxin’s compound AVX001. The compound will be administered once daily in patients with mild to moderate plaque psoriasis vulgaris. As planned, the study will be completed during late spring of 2013. Avexxin has pre-clinical development programs that are advancing other drugs to treat rheumatoid arthritis and glomerulonephritis.

Subscribe to our Newsletter

Thank you!